WilmerHale will host its inaugural Legal Developments Affecting the Life Sciences Industry Conference on Tuesday, October 6. The program will run from 12–4 p.m. and feature firm partners as well as speakers from leading pharmaceutical companies on the following panels:
Trends in Post-Grant Proceedings (optional working lunch)
- Impact of Amgen v. Sandoz on biosimilar IPRs
- Empirical evidence on IPRs against Orange Book listed patents
- Strategies for success in defending IPRs for life sciences companies
Developments in the FTC's Enforcement and Private Antitrust Litigation
- How have courts applied the “rule of reason” standard announced in Actavis?
- What are the emerging antitrust standards governing launch or promotion of "next generation" products, and withdrawal of legacy products?
- REMS: Are innovator drug companies obligated under the antitrust law to provide samples to generics conducting bioequivalence testing for future ANDAs?
Recent Happenings at the Supreme Court and Federal Circuit and What to Look for in the Future
- Discussion and analysis of recent case law from the Supreme Court and Federal Circuit of particular import for the life sciences
- Applicable procedural and ethical rules
- Requirements at various litigation stages, particularly in light of the impending amendments to the Federal Rules of Civil Procedure
- Consequences for the unwary litigant, including potential sanctions, "negative inference" presumptions, rejection of expert testimony or outright dismissal
This educational event will conclude with a networking cocktail reception. CLE credit will be offered, including ethics credit.
